Company Description
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States.
It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster.
It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer’s disease.
In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19.
It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores.
The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
| Country | United States |
| Founded | 1989 |
| IPO Date | Jan 16, 1997 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 96 |
| CEO | Ted Karkus |
Contact Details
Address: 711 Stewart Avenue, Suite 200 Garden City, New York 11530 United States | |
| Phone | 215 345 0919 |
| Website | prophaselabs.com |
Stock Details
| Ticker Symbol | PRPH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000868278 |
| CUSIP Number | 74345W108 |
| ISIN Number | US74345W1080 |
| Employer ID | 23-2577138 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ted William Karkus | Chairman and Chief Executive Officer |
| Lance Bisesar | Corporate Controller |
| Stu Hollenshead | Chief Operating Officer |
| Sergio Miralles | Executive Vice President and Chief Information Officer |
| Kamal Obbad | Senior Vice President and Director of Sales and Marketing - Nebula Genomics |
| Jason Karkus | President of Nebula Genomics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | 10-K/A | [Amend] Annual report |
| Apr 1, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Apr 1, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 28, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 21, 2025 | 8-K | Current Report |
| Feb 13, 2025 | 8-K | Current Report |
| Jan 30, 2025 | 8-K | Current Report |
| Jan 30, 2025 | 424B5 | Filing |